2023.02.20

Navinci appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board

In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.

In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.

Last year and as previously communicated, Navinci took important steps towards accelerating commercialization and market leadership in spatial proteomics. In July, Navinci announced the closing of a SEK 90 million financing led by Segulah Medical Acceleration together with the existing shareholders. In September, the company launched the first commercial assay to accurately detect and visualize the immune checkpoint interaction between the programmed cell death protein 1 (PD1) and PD1-ligand (PD-L1) in tissue samples. The assay launch is the first step in building a complete portfolio of target-specific assays for immune-oncology research and represents a significant advance in spatial proteomics. Rounding out 2022, Navinci released a first of its kind proximity ligation assay, the Naveni TriFlex Cell. The TriFlex assay simultaneously detects individual proteins and their interaction thereby providing a powerful tool to study proteins and their interplay in cells.

In line with the growing focus on commercialization, the company appointed Dr Eva Pisa as new chairman of the board. Dr. Pisa started her career at Karolinska Institute in Stockholm and has 30 years of experience from R&D and commercial roles in diagnostic and life science industries. Dr. Pisa currently serves on the Board of Directors of HSE AG, Switzerland, Envetec Ltd., Ireland and Qiagen NV, Holland. Maria Tell also joins the Board representing Segulah Medical Acceleration. Ms. Tell brings over 15 years of experience in marketing, business strategy, investment, and investor relations within the life science and medtech industries. Navinci also established a Scientific Advisory Board chaired by founder and co-owner, Professor Ulf Landegren. The Scientific Advisory Board members are Professor Jan Anderson, Karolinska Institute, Professor Mats Nilsson, Stockholm University, Professor Carolina Wählby, Uppsala University and Assistant Professor Daniel Fürth, Uppsala University. The group comprises of individuals with deep expertise in the fields of image analysis, in situ technology development and medical research.

The Navinci leadership team, led by CEO Robert Gunnarsson, is strengthened with the recruitment of Dr. Caroline Gallant, taking on a newly formed role as Chief Technology Officer. Dr Gallant joins Navinci from 10X Genomics and brings extensive experience of in situ molecular technology development. Dr. Gallant will lead the companies technology innovation activities, whereas Dr. Agata Zieba Wicher, Chief Scientific Officer, will lead the product development and scientific collaborations. As will be announced shortly, Navinci has recruited a new Chief Business Officer who will lead the organizational build-up and commercialization of the unique Navinci product portfolio.

“I am excited to join Navinci in this dynamic and fast-moving phase. Navinci has an exciting product offering based on unique technology invented by Ulf Landegren and colleagues. The talented team has delivered on the set strategy and goals and created an offer that differentiates Navinci from other actors in the field.  I am looking forward to working with the board of directors and the Navinci team to contribute to increased understanding of the fascinating world of protein interactions.”. – Eva Pisa, Chairman of the Board.

“I am looking forward to working with Eva Pisa on the next exciting part of Navinci´s journey in providing tools to better understand the protein interactions in immune oncology. With the addition of Caroline Gallant to the leadership team and her expertise in this field we have further strengthened our scientific power. I am also pleased that we could attract such outstanding scientific professionals to our Scientific Advisory Board who will provide us with cutting edge knowledge in imaging techniques, molecular tools and bring clinical oncology insights.” – Robert Gunnarsson, CEO of Navinci Diagnostics AB.

Press release

Segulah Medical Acceleration announces investment in Senzime

2023.09.28

Segulah Medical Acceleraion AB (“SMA”) has made a commitment regarding an investment in Senzime AB (publ) (“Senzime” or “the Company”). As previously communicated in a press release from the Company, Senzime’s board of directors has resolved on a directed share issue of SEK 117 million, led by SMA together with Carnegie Fonder and existing shareholders Fjärde AP-fonden, Crafoordska Stiftelsen, Handelsbanken Fonder, Fredrik Rapp, and Swedbank Robur.

Read more

Collective Minds Radiology announces closing of SEK 84m financing, led by Segulah Medical Acceleration and existing shareholders

2023.08.28

Collective Minds Radiology, a fast-growing, Swedish health-tech company with a mission to build the world’s largest platform and community for healthcare collaboration, announces the closing of a SEK 84 million funding round. The round was led by Segulah Medical Acceleration (“SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, Brightly Ventures, Tradecity, Crista Galli Ventures, and several European business angels. The funding will enable Collective Minds to accelerate the commercial expansion of its professional healthcare collaboration platform for clinical consultation, education, and clinical research, with the aim of increasing the quality of care.

Read more

Navinci appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board

2023.02.20

In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.

Read more

Allurion to Go Public on NYSE

2023.02.16

SMA portfolio company Allurion Technologies, a global leader in weight loss technology, to become publicly listed through business combination

Read more

Segulah Medical Acceleration Announces Investment in Allurion Technologies

2022.09.13

Segulah Medical Acceleration AB (“SMA”) has made a minority investment in US-based Allurion Technologies during their July 2021 extension of the $34m Series D financing. The Series D round was led by Novalis LifeSciences and Romulus Capital.

Read more

Segulah Medical Acceleration Announces Investment in Navinci Diagnostics

2022.07.12

Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.

Read more

Signifier Medical Technologies is granted HCPCS Codes

2022.02.28

Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technology

Read more

Segulah Medical Acceleration Announces Investment in Signifier Medical Technologies

2021.07.30

Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.

Read more

Segulah Medical Acceleration Announces Investment in SAGA Diagnostics

2021.06.30

Segulah Medical Acceleration AB (SMA) announced today that it has invested in cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million (€10.5 million) Series A2 equity financing round. The round was led by SMA together with the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.

Read more

Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies

2021.06.28

Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.

Read more

Blue chip investors back new MedTech investment company

2021.04.29

Segulah Medical Acceleration, SMA, is a newly formed company specializing in medical technology investments, with a focus on Sweden, Scandinavia and Western Europe. The company is financed by leading institutions and prominent private investors, whose initial commitments amount to approximately SEK 1.2 billion.

Read more